Windward Bio has raised $165 million to advance a China-derived drug into a Phase 3 asthma trial, according to the company’s latest funding update. The Swiss biotech, which couples an external portfolio with an in-house discovery team, is using the capital to push one of its lead programs into late-stage development. The move underscores how cross-border pipelines are increasingly reaching pivotal studies in respiratory medicine, with sponsors betting that early signals and translational momentum can support a Phase 3 path. For biotech investors and partners, the funding size and Phase 3 timing are key indicators of de-risking progress and manufacturing readiness planning. With only limited details included in the announcement, the near-term watch item will be the trial design—especially endpoints, comparator strategy, and enrollment criteria that will determine how competitively the Phase 3 data could support future regulatory discussions.